VIVO (VivoPower PLC Class A Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by VIVO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-31 | John P. Kenny | Chief Executive Officer | MIXED | — | — |
| 2023-01-31 | Felicia Williams | Director | D | — | — |
| 2023-01-31 | LOURDES WELTZIEN | Executive VP, Life Science | MIXED | — | — |
| 2023-01-31 | Catherine Sazdanoff | Director | D | — | — |
| 2023-01-31 | Anthony P Bihl III | Director | D | — | — |
| 2023-01-31 | Tony Serafini-Lamanna | Executive VP-Diagnostics | MIXED | — | — |
| 2023-01-31 | Julie Diana Smith | Sr VP, Controller, PAO | MIXED | — | — |
| 2023-01-31 | Andrew S. Kitzmiller | Executive Vice President & CFO | MIXED | — | — |
| 2023-01-31 | John McCune Rice Jr. | Director | D | — | — |
| 2023-01-31 | John McIlwraith | Director | D | — | — |
| 2023-01-31 | James M. Anderson | Director | D | — | — |
| 2023-01-31 | Dwight E Ellingwood | Director | D | — | — |
| 2023-01-09 | James M. Anderson | Director | M | — | — |
| 2022-12-07 | Julie Diana Smith | Sr VP, Controller, PAO | F | — | — |
| 2022-11-17 | LOURDES WELTZIEN | EVP, Life Science | F | — | — |
| 2022-11-17 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | — | — |
| 2022-11-17 | Julie Diana Smith | Sr VP, Controller, PAO | F | — | — |
| 2022-11-08 | John P. Kenny | Chief Executive Officer | F | — | — |
| 2022-11-08 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | — | — |
| 2022-11-08 | Julie Diana Smith | Sr VP, Controller, PAO | F | — | — |
| 2022-11-08 | LOURDES WELTZIEN | EVP, Life Science | F | — | — |
| 2022-10-05 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | — | — |
| 2022-10-05 | John P. Kenny | Chief Executive Officer | F | — | — |
| 2022-10-05 | Julie Diana Smith | Sr VP, Controller, PAO | F | — | — |
| 2022-06-28 | John P. Kenny | Chief Executive Officer | MIXED | — | — |
| 2022-06-24 | John P. Kenny | Chief Executive Officer | MIXED | — | — |
| 2022-02-28 | Andrew S. Kitzmiller | EVP & CFO | Buy | — | — |
| 2022-02-22 | Andrew S. Kitzmiller | EVP & CFO | A | — | — |
| 2022-02-17 | LOURDES WELTZIEN | EVP, Life Science | MIXED | — | — |
| 2022-01-28 | Felicia Williams | Director | A | — | — |
| 2022-01-28 | John McCune Rice Jr. | Director | A | — | — |
| 2022-01-28 | John McIlwraith | Director | A | — | — |
| 2022-01-28 | Anthony P Bihl III | Director | A | — | — |
| 2022-01-28 | Catherine Sazdanoff | Director | A | — | — |
| 2022-01-28 | James M. Anderson | Director | A | — | — |
| 2022-01-28 | Dwight E Ellingwood | Director | A | — | — |
| 2022-01-14 | DAVID PHILLIPS | Director | M | — | — |
| 2021-12-22 | Bryan T Baldasare | Exec VP & CFO | F | — | — |
| 2021-12-22 | LOURDES WELTZIEN | EVP, Life Science | F | — | — |
| 2021-12-16 | LOURDES WELTZIEN | EVP, Life Science | F | — | — |
| 2021-12-16 | Tony Serafini-Lamanna | Executive VP-Diagnostics | F | — | — |
| 2021-12-16 | Bryan T Baldasare | Exec VP & CFO | F | — | — |
| 2021-11-16 | Bryan T Baldasare | Exec VP & CFO | MIXED | — | — |
| 2021-11-16 | Tony Serafini-Lamanna | Executive VP-Diagnostics | MIXED | — | — |
| 2021-11-16 | John P. Kenny | Chief Executive Officer | MIXED | — | — |
| 2021-11-16 | LOURDES WELTZIEN | EVP, Life Science | MIXED | — | — |
| 2021-11-08 | LOURDES WELTZIEN | EVP, Life Science | A | — | — |
| 2021-11-08 | John P. Kenny | Chief Executive Officer | A | — | — |
| 2021-11-08 | Tony Serafini-Lamanna | Executive VP-Diagnostics | A | — | — |
| 2021-11-08 | Bryan T Baldasare | Exec VP & CFO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Executive Chairman | 340,811 | — |
| — | Exec VP, CFO | 169,776 | — |
| — | EVP, Global Reg & Quality Syst | 168,280 | — |
| — | Director | 101,154 | — |
| — | Executive VP, Life Science | 86,045 | — |
| — | EVP, Global Operations | 75,528 | — |
| — | Pres & Managing Director, MBE | 64,057 | — |
| — | Exec VP & CFO | 60,929 | — |
| — | EVP, R&D & Chf Scientific Off | 56,069 | — |
| — | EVP; Pres, Chief Comm Officer | 53,348 | — |
| — | Executive VP-Diagnostics | 43,338 | — |
| — | EVP, Pres Meridian Global Dx | 29,000 | — |
| — | EVP, Pres & CEO of Magellan | 22,500 | — |
| — | EVP, Bus. Development/Strategy | 22,500 | — |
| — | Executive Vice President & CFO | 19,473 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VIVO quote page; the site-wide leaderboard is on the insider transactions hub.